Navigation Links
Blood flow in Alzheimer's disease
Date:7/27/2009

Researchers have discovered that the enzyme, endothelin converting enzyme-2 (ECE-2), may cause the decrease in blood flow in the brain seen in Alzheimer's disease and contribute to progression of the disease.

The study by Jennifer Palmer, BRACE/Reverend Williams PhD Scholar and colleagues at the University of Bristol's Dementia Research Group is published in the current issue [July 2009] of the American Journal of Pathology.

Alzheimer's disease is the most common form of dementia, affecting over half a million people in the UK - a figure expected to double in the next 20 years. Aβ peptide, which accumulates in the brain of Alzheimer's disease patients, is thought to lead to narrowing of the blood vessels and reduction of blood flood in the brain. ECE-2 may contribute to the disease by converting an inactive precursor to endothelin-1, which constricts blood vessels and further reduces blood flow.

Jennifer Palmer said: "Our findings raise the possibility that drugs that can block the actions of endothelin-1 and which are already licensed for treating other diseases may also be of benefit for the treatment of Alzheimer's disease."

Much of the funding for Jennifer Palmer's work comes from Bristol-based charity BRACE. The charity's Chief Executive, Mark Poarch added: "This is real progress and opens up new areas for research. It is also good news for the thousands of local people who have raised money to try to beat Alzheimer's. BRACE is stepping up its fundraising to help scientists press on and find a cure."

The researchers had been studying ECE-2 in human brain tissue that was donated to the South West Dementia Brain Bank at the University of Bristol because the enzyme is also able to break down Aβ peptide, which accumulates in Alzheimer's disease. They found that ECE-2 was markedly elevated in Alzheimer's disease. ECE-2 was particularly abundant in nerve cells in a part of the brain that is critical for memory and is severely affected by Alzheimer's disease.

The increase in ECE-2 in Alzheimer's disease is not simply a by-product of nerve cell damage. When the researchers looked at brain tissue from patients with a different type of dementia (vascular dementia), ECE-2 levels were normal no different from the levels in brain tissue from elderly people without dementia. Further studies showed that the increase seen in Alzheimer's disease of ECE-2 could not be explained by differences in age, gender or time to brain removal after death between the various groups of patients that were studied.

To investigate why ECE-2 might be specifically elevated in Alzheimer's disease, the researchers then examined nerve cells that were grown in a laboratory. They showed that addition of Aβ caused these nerve cells to increase their production of ECE-2. The findings indicate that nerve cells produce more ECE-2 when they are exposed to Aβ.

In the normal brain, blood flow responds to nerve cell activity. If nerve cell activity in a particular part of the brain increases, so does the supply of blood that is needed to meet the extra demand for nutrients such as glucose and oxygen. If this demand is not met, as can happen in Alzheimer's disease, the nerve cells may not function normally and may even sicken and die.

Although the elevated ECE-2 in Alzheimer's disease may help to break down amyloid beta, it may also cause the decrease in blood flow in the brain, through the production of too much endothelin-1. This may have important implications for treatment. Drugs are available that can block the actions of endothelin-1 and which have been shown to treat some other diseases in which excess endothelin-1 reduces blood flow. The findings raise the possibility that these drugs may also be of benefit for the treatment of Alzheimer's disease.


'/>"/>

Contact: Joanne Fryer
joanne.fryer@bristol.ac.uk
44-117-331-7276
University of Bristol
Source:Eurekalert

Related medicine news :

1. Alcohol and Trauma: Blood Test Gets to the Truth
2. Bone from blood: Circulating cells form bone outside the normal skeleton, Penn study finds
3. KLOS & Red Cross Set to Rock SoCal With Massive 5 Day Blood Drive
4. Gene Mutation Could Be Key to Rare Blood Vessel Disease
5. Cord Blood America CEO Discusses New State-of-the-Art State Laboratory in Fox News Television Interview
6. Orlando Regional Medical Center (ORMC) Implements PNA FISH(R) Tests to Help Provide Better Care for Patients with Bloodstream Infections
7. Gene linked to increasingly common type of blood cancer
8. High-Salt Diet Dampens Effects of Blood Pressure Drugs
9. Need for At-Home Blood Pressure Monitoring Underscored by High-Profile Cardiac Deaths
10. Cord Blood America Highlights Significant 2009 Progress
11. Blood Test Shows Statistically Significant Association With Alzheimers Disease (AD), May Predict Conversion of Mild Cognitive Impairment to AD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... ... April 28, 2016 , ... Greener Hydroponics is now offering a ... frequently used by professional organic farmers and nurseries according to Sales Manager Joe Steele ... fabric pots. Our goal is to offer wholesale level pricing and ultra-fast shipping for ...
(Date:4/28/2016)... Illinois (PRWEB) , ... April ... ... the leading provider of enterprise Data Center Infrastructure Management solutions, announces today ... focuses on feature enhancements in the area of capacity management and optimization, ...
(Date:4/28/2016)... ... ... reminds us that May is National Stroke Awareness Month. According to the Centers for ... the United States; someone has one every 40 seconds. Annually, almost 800,000 strokes occur ... A stroke is when blood flow to the brain is blocked or when a ...
(Date:4/28/2016)... ... April 28, 2016 , ... A first-time look at workers’ compensation claims in ... Workers Compensation Research Institute (WCRI) announced, and that costs per claim were ... Kentucky, 16th Edition , found that indemnity costs per claim and benefit delivery expenses ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... it will demonstrate its leading secure mobility workstation suite, SentinelSecure™, at MobileIron’s 6th ... Hilton Union Square, this will be MobileIron’s 6th Mobile First Conference and will ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , April 28, 2016  The blood testing market ... dollars, according to Kalorama Information and The Freedonia Group ... and nucleic acid testing.  The healthcare research firm said ... in developing blood collection stations and in improving testing ... Kalorama Information,s report, Blood Testing Market in ...
(Date:4/28/2016)... April 28, 2016   Acsis , a leading ... leading IT market research and advisory firm IDC has ... IDC MarketScape: Worldwide Pharmaceutical Track and Trace Software 2016 ... provides an assessment of the capabilities and business strategies ... software market. Logo - http://photos.prnewswire.com/prnh/20160427/360791LOGO ...
(Date:4/27/2016)... , Schweiz, April 27, 2016 ... Sachs CEO Forums in Zürich gab Strekin ... führenden Wirkstoffkandidaten STR001 zur Erhaltung des Resthörvermögens ... wurde, bekannt. Für die umfassende Phase-II-Doppelblindstudie mit ... Frankreich angeworben. STR001 wird während der Operation ...
Breaking Medicine Technology: